A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours

被引：0
|
作者：
de Bono, J. S. [1 ,2 ]
Lord, S. [3 ]
Yap, C. [4 ]
Miranda, S. [5 ]
Veal, G. J. [6 ]
Chandran, K. [7 ]
Paschalis, A. [8 ]
Peron, C. [9 ]
Rekowski, J. [10 ]
Gurel, B. [5 ]
Paisley, D. [11 ]
McGuigan, L. [12 ]
Ingram, P. J. [13 ]
Kwek, K. Y. [14 ]
Halbert, G. [12 ]
Westwood, N. B. [12 ]
Griffin, A. E. [11 ]
Kostaras, L. [11 ]
Boyd-Kirkup, J. D. [15 ]
Walter, H. S. [11 ]
机构：
[1] Inst Canc Res, Prostate Canc Targeted Therapies Grp, Sutton, England
[2] Royal Marsden Hosp, Sutton, England
[3] Univ Oxford, Dept Oncol, Oxford, England
[4] ICR Inst Canc Res North Site, Clin Trials Biostat Dept, Sutton, England
[5] ICR Inst Canc Res, Clin Studies Canc Biomarkers, London, England
[6] Newcastle Univ, Newcastle Univ Ctr Canc, Newcastle Upon Tyne, England
[7] Royal Marsden Hosp NHS Fdn, Prostate Canc Targeted Therapies Grp, Sutton, England
[8] ICR Inst Canc Res, Clin Studies, London, England
[9] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford, England
[10] ICR Inst Canc Res, Clin Trials & Stat Unit, London, England
[11] CRUK Canc Res UK, Ctr Drug Dev, London, England
[12] Canc Res UK, Ctr Drug Dev, London, England
[13] Hummingbird Biosci Pte Ltd Temasek Lifesci Labs, Singapore, Singapore
[14] Hummingbird Biosci, Clin Dev, Singapore, Singapore
[15] Hummingbird Biosci Pte Ltd Temasek Lifesci Labs, Res, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1873
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687P
引用
收藏
页码：S479 / S480
页数：2
相关论文
共 50 条
  • [1] A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours
    de Bono, J. S.
    Lord, S.
    Yap, C.
    Rowinsky, E. K.
    Gandhi, N. A.
    Thakkar, D.
    Ingram, P. J.
    Padmanabhan, N.
    Chandran, K.
    Paschalis, A.
    McGuigan, L.
    Neal, P.
    Paisley, D.
    Walter, H. S.
    Kelly, F.
    Craigan, J.
    Westwood, N. B.
    Halbert, G.
    Boyd-Kirkup, J. D.
    Halford, S. E. R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S767 - S767
  • [2] Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
    Idowu, O.
    Craigen, J.
    Svetlik, S.
    Veal, J.
    Jamieson, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
  • [3] Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum
    Idowu, Oladipo S.
    Craigen, Jenny L.
    Veal, Gareth J.
    Jamieson, David
    BIOANALYSIS, 2022, 14 (18) : 1241 - 1249
  • [4] Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous NonSmall Cell Lung Cancer
    Pavlakis, N.
    Kichenadasse, G.
    Richardson, G.
    Bowyer, S.
    Andelkovic, V.
    Ganju, V.
    Tan, A.
    Samol, J.
    Thomas, D.
    Fernandez, A. Mas
    Paszkiewicz, K.
    Ingram, P.
    Boyd-Kirkup, J.
    Kwek, K. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S350 - S350
  • [5] A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
    Pavlakis, N.
    Millward, M.
    Richardson, G.
    Andelkovic, V.
    Kichenadasse, G.
    Thomas, D. M.
    Fernandez, A. Mas
    Thakkar, D.
    Arbabzade, T.
    Goey, C. H.
    Seet, Q.
    Toy, W.
    Paszkiewicz, K.
    Ingram, P. J.
    Boyd-Kirkup, J. D.
    Kwek, K. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1501 - S1501
  • [6] Combining Anti-HER3 Antibody, HMBD-001, with EGFR Inhibition and Chemotherapy may Improve Treatment Outcomes in SqNSCLC
    Toy, W.
    Thakkar, D.
    Luu, K.
    Bui, N. L. C.
    Chau, K. F.
    Lai, J.
    Ray, D.
    Wu, S.
    Poi, M.
    Gandhi, N. A.
    Mas, A.
    Paszkiewicz, K.
    Ingram, P.
    Boyd-Kirkup, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S208 - S209
  • [7] First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
    Meulendijks, Didier
    Jacob, Wolfgang
    Martinez-Garcia, Maria
    Taus, Alvaro
    Lolkema, Martijn P.
    Voest, Emile E.
    Langenberg, Marlies H. G.
    Fleitas Kanonnikoff, Tania
    Cervantes, Andres
    De Jonge, Maja J.
    Sleijfer, Stefan
    Soerensen, Morten Mau
    Thomas, Marlene
    Ceppi, Maurizio
    Meneses-Lorente, Georgina
    James, Ian
    Adessi, Celine
    Michielin, Francesca
    Abiraj, Keelara
    Bossenmaier, Birgit
    Schellens, Jan H. M.
    Weisser, Martin
    Lassen, Ulrik N.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 877 - 885
  • [8] Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
    Denlinger, Crystal S.
    Keedy, Vicki L.
    Moyo, Victor
    MacBeath, Gavin
    Shapiro, Geoffrey, I
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1604 - 1612
  • [9] Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
    Crystal S. Denlinger
    Vicki L. Keedy
    Victor Moyo
    Gavin MacBeath
    Geoffrey I. Shapiro
    Investigational New Drugs, 2021, 39 : 1604 - 1612
  • [10] Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
    LoRusso, Patricia
    Jaenne, Pasi A.
    Oliveira, Moacyr
    Rizvi, Naiyer
    Malburg, Lisa
    Keedy, Vicki
    Yee, Lorrin
    Copigneaux, Catherine
    Hettmann, Thore
    Wu, Chi-Yuan
    Ang, Agnes
    Halim, Abdel-Baset
    Beckman, Robert A.
    Beaupre, Darrin
    Berlin, Jordan
    CLINICAL CANCER RESEARCH, 2013, 19 (11) : 3078 - 3087
12345